STOCK TITAN

Erasca (NASDAQ: ERAS) counsel Ebun Garner reports option exercise and share sale

Filing Impact
(High)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

Erasca, Inc. General Counsel & Corporate Secretary Ebun Garner reported several equity transactions in company stock. On December 15, 2025, Garner acquired 3,902 shares of common stock at $1.1943 per share under Erasca's 2021 Employee Stock Purchase Plan. On January 7, 2026, Garner exercised 120,000 stock options at an exercise price of $1.7 per share and, on the same date, sold 120,000 shares of common stock at a weighted-average price of $5.5901 per share pursuant to a previously adopted Rule 10b5-1 trading plan. Following these transactions, Garner directly held 25,076 shares of common stock and 360,000 stock options that are fully vested and exercisable.

Positive

  • None.

Negative

  • None.
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Garner Ebun

(Last) (First) (Middle)
C/O ERASCA, INC.
3115 MERRYFIELD ROW, SUITE 300

(Street)
SAN DIEGO CA 92121

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Erasca, Inc. [ ERAS ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
General Counsel & Corp. Sec.
3. Date of Earliest Transaction (Month/Day/Year)
12/15/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 12/15/2025 A 3,902 A $1.1943(1) 25,076 D
Common Stock 01/07/2026 M(2) 120,000 A $1.7 145,076 D
Common Stock 01/07/2026 S(2) 120,000 D $5.5901(3) 25,076 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (right to buy) $1.7 01/07/2025 M(2) 120,000 (4) 02/04/2034 Common Stock 120,000 $0 360,000 D
Explanation of Responses:
1. The purchase price was calculated in accordance with the Issuer's 2021 Employee Stock Purchase Plan.
2. The exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on June 30, 2024.
3. This represents a weighted-average price. These shares were sold in multiple transactions at prices ranging from $5.50 to $5.80. The Reporting Person undertakes to provide the Issuer, any securityholder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
4. The shares subject to this option award are fully vested and exercisable as of the date hereof.
/s/ Ebun Garner 01/08/2026
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did Erasca (ERAS) report for Ebun Garner?

Ebun Garner reported three main transactions: a purchase of 3,902 shares under the employee stock purchase plan, the exercise of 120,000 stock options, and the sale of 120,000 shares of Erasca common stock.

On what dates did Ebun Garner trade Erasca (ERAS) stock?

Garner acquired shares on December 15, 2025 and both exercised options and sold shares on January 7, 2026.

What prices were involved in Ebun Garner’s Erasca (ERAS) transactions?

The employee stock purchase was at $1.1943 per share, the option exercise price was $1.7 per share, and the 120,000 shares sold had a weighted-average sale price of $5.5901 per share.

How many Erasca (ERAS) shares does Ebun Garner hold after these transactions?

After the reported transactions, Garner directly beneficially owned 25,076 shares of Erasca common stock.

What stock options related to Erasca (ERAS) does Ebun Garner still hold?

Garner held 360,000 stock options following the reported exercise. These options relate to Erasca common stock and are fully vested and exercisable.

Were Ebun Garner’s Erasca (ERAS) trades under a Rule 10b5-1 plan?

Yes. The filing states that the option exercise and share sales on January 7, 2026 were effected under a Rule 10b5-1 trading plan adopted on June 30, 2024.

How were the employee stock purchase shares in Erasca (ERAS) priced for Ebun Garner?

The filing notes that the purchase price for the 3,902 shares acquired on December 15, 2025 was calculated in accordance with Erasca’s 2021 Employee Stock Purchase Plan at $1.1943 per share.

Erasca, Inc.

NASDAQ:ERAS

ERAS Rankings

ERAS Latest News

ERAS Latest SEC Filings

ERAS Stock Data

1.92B
227.87M
11.68%
81.93%
6.6%
Biotechnology
Pharmaceutical Preparations
Link
United States
SAN DIEGO